Technology

Compugen Doubles Quarterly Revenue as Cancer Programs Advance

Published

Courtroom-sketch editorial illustration of a laboratory technician in blue protective clothing pipetting a blood sample beside racks of capped sample tubes.

Compugen reported second-quarter revenue of $2.6 million, double the $1.3 million recorded a year earlier, while its net loss narrowed to $7.0 million from $7.3 million. The Holon cancer-immunotherapy company ended June with $125.3 million in cash and investments, no debt, and expects its runway to fund operations into 2029. Its COM701 MAIA-ovarian trial remains on track for interim median progression-free-survival data by the first quarter of 2027. Partner AstraZeneca added another Phase 3 rilvegostomig trial and presented the antibody's first overall-survival readout, while the Gilead-partnered GS-0321 Phase 1 study continued as planned.

Sources

Primary sources:1

Something went wrong

We couldn't complete that action. Check your connection and try again.